Hoechst Adopts Subtle Approach to French Generics
German pharmaceutical major Hoechst AG, which is gradually disengagingitself from the generics drug business worldwide, has adapted to French government policy on generics after launching a generics subsidiary of its French Hoechst Marion Roussel unit a year ago. However, HMR and its generics company, Cox France, are maintaining a lower profile than in 1996, and Cox has so far not launched a single product.
It now appears that rather than operate through its own company structure, HMR has signed a letter of intent to join the existing generics alliance between Sanofi and Hexal of Germany. Negotiations are currently underway.
HMR already has a company - Qualimed - specializing in generics for the hospital sector. Qualimed reported sales of 30 million French francs ($5.1 million) last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze